[{"id":"868a48c8-2833-439b-b24b-719061743a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05113290","created_at":"2021-11-09T12:53:05.983Z","updated_at":"2024-07-02T16:36:17.880Z","phase":"Phase 4","brief_title":"Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment","source_id_and_acronym":"NCT05113290","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Oncorine (recombinant human adenovirus type 5)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 12/28/2021","start_date":" 12/28/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-01-27"}]